Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...
The discussion opens with an overview of the evolving management of high-risk non–muscle invasive bladder cancer (NMIBC) and introduces the session’s goals of reviewing the treatment landscape, recent ...
The ExactVu micro-ultrasound platform is noninferior to MRI in detecting clinically significant prostate cancer in biopsy-naïve men. Microultrasonography offers a cost-effective, in-office alternative ...
Treatment intensification with ARPIs and chemotherapy has transformed mCSPC management, expanding the urologist's role in early treatment phases. Darolutamide is highlighted for its favorable safety ...
In an interview at the 2025 LUGPA Annual Meeting, Stacy Loeb, MD, shared key takeaways from her session, “Current state of prostate cancer screening.” Loeb is a urologists at NYU Langone Health in New ...
Nanopath's assay for cUTIs has received FDA breakthrough device designation, indicating its potential to significantly advance UTI diagnosis. The assay aims to deliver molecular results in 15 minutes, ...
Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation. In this video, urologist Jonathan Henderson, MD, of Arkansas Urology in Little Rock, reflects on ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
The 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, delivered several noteworthy data readouts in genitourinary oncology. Prostate cancer in particular saw a wave of ...
Gedatolisib and darolutamide combination targets PAM and AR pathways, potentially inducing a synergistic anti-tumor effect in mCRPC patients. Phase 1 trial with 38 patients showed promising safety, ...
Fast track designation accelerates development of [68Ga]Ga-DPI-4452 for ccRCC detection, enhancing FDA engagement and review processes. ITM-94, a gallium-68-radiolabeled PET agent, forms a theranostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback